2.50
Hdl Handle:
http://hdl.handle.net/10541/99105
Title:
Melanoma: chemotherapy.
Authors:
Lee, Siow Ming; Betticher, Daniel C; Thatcher, Nick
Abstract:
The overall median survival of patients with systemic metastasis from melanoma is about 6 months. Survival is dependent on the sites of first metastasis, the resectability of the metastases, and the number of metastases. Patients with non-visceral metastases at first relapse i.e. in skin, subcutaneous tissues, distant lymph nodes, and lung, have a better survival rate than patients with visceral (liver, bone, brain) metastases. Treatment of patients with systemic melanoma should include careful evaluation for the potential role of surgery, radiotherapy, and systemic therapy. The main use of chemotherapy in metastatic melanoma patients remains palliative. The chapter reviews the chemotherapeutic options available for the treatment of malignant melanoma including recent published works on new agents, multi-agent therapy, high dose chemotherapy with autologous bone marrow rescue, adjuvant chemotherapy and regional perfusion chemotherapy.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester.
Citation:
Melanoma: chemotherapy. 1995, 51 (3):609-30 Br. Med. Bull.
Journal:
British Medical Bulletin
Issue Date:
Jul-1995
URI:
http://hdl.handle.net/10541/99105
PubMed ID:
7552084
Type:
Article
Language:
en
ISSN:
0007-1420
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorLee, Siow Mingen
dc.contributor.authorBetticher, Daniel Cen
dc.contributor.authorThatcher, Nicken
dc.date.accessioned2010-05-18T12:36:58Z-
dc.date.available2010-05-18T12:36:58Z-
dc.date.issued1995-07-
dc.identifier.citationMelanoma: chemotherapy. 1995, 51 (3):609-30 Br. Med. Bull.en
dc.identifier.issn0007-1420-
dc.identifier.pmid7552084-
dc.identifier.urihttp://hdl.handle.net/10541/99105-
dc.description.abstractThe overall median survival of patients with systemic metastasis from melanoma is about 6 months. Survival is dependent on the sites of first metastasis, the resectability of the metastases, and the number of metastases. Patients with non-visceral metastases at first relapse i.e. in skin, subcutaneous tissues, distant lymph nodes, and lung, have a better survival rate than patients with visceral (liver, bone, brain) metastases. Treatment of patients with systemic melanoma should include careful evaluation for the potential role of surgery, radiotherapy, and systemic therapy. The main use of chemotherapy in metastatic melanoma patients remains palliative. The chapter reviews the chemotherapeutic options available for the treatment of malignant melanoma including recent published works on new agents, multi-agent therapy, high dose chemotherapy with autologous bone marrow rescue, adjuvant chemotherapy and regional perfusion chemotherapy.en
dc.language.isoenen
dc.subjectSkin Canceren
dc.subject.meshAntineoplastic Agents-
dc.subject.meshChemotherapy, Cancer, Regional Perfusion-
dc.subject.meshDrug Resistance-
dc.subject.meshHumans-
dc.subject.meshMelanoma-
dc.subject.meshSkin Neoplasms-
dc.titleMelanoma: chemotherapy.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester.en
dc.identifier.journalBritish Medical Bulletinen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.